Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31378728 | 0.84 | PIK3CG (0.44) | PDGFRBPDGFRANR4A2PIK3CGLMNA | |
| SCHEMBL30668491 | 0.81 | MEN1 (0.60) | LMNAMAPTALOX15EGFRPLAU | |
| SCHEMBL10979440 | 0.81 | MEN1 (0.60) | LMNAMAPTALOX15EGFRPLAU | |
| SCHEMBL7157574 | 0.81 | PDGFRB (0.59) | PDGFRBPDGFRANR4A2PIK3CGLMNA | |
| SCHEMBL30702581 | 0.81 | PDGFRB (0.59) | PDGFRBPDGFRANR4A2PIK3CGLMNA | |
| SCHEMBL14908778 | 0.76 | HTT (0.54) | PDGFRBPDGFRANR4A2LMNAMAPT | |
| SCHEMBL4159996 | 0.76 | PDGFRB (0.51) | PDGFRBPDGFRALMNACYP1A2MAPT | |
| SCHEMBL7882970 | 0.76 | ESR2 (0.59) | PDGFRBPDGFRALMNAMAPTTHRB | |
| SCHEMBL4539841 | 0.76 | KDM4E (0.52) | LMNACYP1A2MAPTALOX15MAPK1 | |
| SCHEMBL31378776 | 0.76 | ALDH1A1 (0.50) | LMNACYP1A2MAPTMAPK1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108484497-B | Synthetic method of 3-amino-7-chloroquinoline | 苏州康润医药有限公司 | 2021-05-04 | — | — | CN | claimed |
| CN-108484497-A | A kind of synthetic method of 3- amino -7- chloroquinolines | 苏州康润医药有限公司 | 2018-09-04 | — | — | CN | claimed |
| US-20220354857-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| CN-108484497-B | Synthetic method of 3-amino-7-chloroquinoline | 苏州康润医药有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-108484497-B | Synthetic method of 3-amino-7-chloroquinoline | 苏州康润医药有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-108484497-B | Synthetic method of 3-amino-7-chloroquinoline | 苏州康润医药有限公司 | 2021-05-04 | — | — | CN | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| CN-108484497-A | A kind of synthetic method of 3- amino -7- chloroquinolines | 苏州康润医药有限公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-108484497-A | A kind of synthetic method of 3- amino -7- chloroquinolines | 苏州康润医药有限公司 | 2018-09-04 | — | — | CN | disclosed |
| WO-2008041088-A2 | N-HYDROXY BENZAMIDES WITH ANTITUMOR ACTIVITY | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | PDGFRB 4727/4885PDGFRA 4752/4885NR4A2 3882/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | PDGFRB 4727/4885PDGFRA 4752/4885NR4A2 3882/4885 |
| US-20220354857-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDH1A2, AOX1, ALDH2 | PDGFRB 2579/4885PDGFRA 2369/4885NR4A2 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.